World of DTC Marketing

APRIL 7, 2022

Right now, voters are worried about inflation and rising fuel prices, but they ignore the imminent threats to their healthcare. American healthcare continues to be under assault, and unless we address these issues, a severe health issue could bankrupt families. THREAT 3: RISING HEALTHCARE COSTS. THREAT 1: OBESITY AND DIABETES.

Healthcare 215

Healthcare Healthcare Food and Drug Administration Government 215

European Pharmaceutical Review

SEPTEMBER 22, 2022

Rare disease drug development poses unique challenges that can be overcome by using real-world evidence (RWE). Additionally, healthcare payers understand that HCs can provide value by describing potential treatment benefit relative to untreated patients in their populations.

Food and Drug Administration 114

Food and Drug Administration Patients Distribution FDA 114

European Pharmaceutical Review

MARCH 8, 2023

After moving to London in 2011, Ekaterina worked in global health and medical philanthropy, focusing on improving outcomes in maternal and child health. At COMPASS, I currently oversee the development of innovative therapies which includes drug development, and innovations more broadly to support drug delivery, such as digital innovation.

Leads 52

Leads Pharma Food and Drug Administration Medicine 52

Clarivate

MAY 24, 2022

Recent policy and regulatory moves have begun to sketch out a framework for rare disease drug approvals in the country, but obstacles to approvals and patient access remain. The list, designed to serve as a reference point for prioritized drug review and evaluation policies, included 121 rare diseases. [8]. 10] [11] [12].

Patients 52

Patients Food and Drug Administration Marketing Pharma 52

pharmaphorum

SEPTEMBER 13, 2022

Thanks to the dedicated efforts of doctors, patients, carers, and healthcare professionals, people diagnosed with blood cancer are now living longer, with a steady stream of more effective treatments entering the market each year. 2001– FDA green lights revolutionary treatments. 2002 – Emergence of CAR-T therapy.

Food and Drug Administration 94

Food and Drug Administration Patients Engineering Physicians 94

European Pharmaceutical Review

SEPTEMBER 22, 2023

Limitations of monoclonal antibody therapies Regulatory approvals from the US Food and Drug Administration (FDA) for aducanumab and lecanemab – and likely very soon for donanemab also – opened a route for different therapeutic modalities and other relevant disease targets, such as tau.

Food and Drug Administration 78

Food and Drug Administration Safety Patients Leads 78